Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine
Authors
Keywords
-
Journal
mBio
Volume 9, Issue 2, Pages -
Publisher
American Society for Microbiology
Online
2018-03-12
DOI
10.1128/mbio.00036-18
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains
- (2017) Shannon L. Harris et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France
- (2017) Muhamed-Kheir Taha et al. VACCINE
- Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined
- (2016) Massimiliano Biagini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Meningococcal serogroup B vaccines: Estimating breadth of coverage
- (2016) Robert G. K. Donald et al. Human Vaccines & Immunotherapeutics
- Resistance of Neisseria meningitidis to Human Serum Depends on T and B Cell Stimulating Protein B
- (2015) Maike G. Müller et al. INFECTION AND IMMUNITY
- Serum bactericidal antibody assays – The role of complement in infection and immunity
- (2015) E.D.G. McIntosh et al. VACCINE
- The Discovery and Development of a Novel Vaccine to Protect againstNeisseria meningitidisSerogroup B Disease
- (2014) Gary W Zlotnick et al. Human Vaccines & Immunotherapeutics
- Three-Dimensional Structure and Biophysical Characterization of Staphylococcus aureus Cell Surface Antigen–Manganese Transporter MntC
- (2013) Alexey Gribenko et al. JOURNAL OF MOLECULAR BIOLOGY
- Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment
- (2013) Ulrich Vogel et al. LANCET INFECTIOUS DISEASES
- Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease
- (2013) L. K. McNeil et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- A Multi-country Evaluation of Neisseria meningitidis Serogroup B Factor H–Binding Proteins and Implications for Vaccine Coverage in Different Age Groups
- (2013) Susan K. Hoiseth et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults
- (2013) Helen S. Marshall et al. VACCINE
- Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial
- (2012) Peter C Richmond et al. LANCET INFECTIOUS DISEASES
- A Randomized, Controlled, Phase 1/2 Trial of a Neisseria meningitidis Serogroup B Bivalent rLP2086 Vaccine in Healthy Children and Adolescents
- (2012) Michael D. Nissen et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial
- (2012) P.C. Richmond et al. VACCINE
- Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States
- (2011) Xin Wang et al. VACCINE
- Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage
- (2010) Dlawer A.A. Ala’Aldeen et al. VACCINE
- Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
- (2010) Han-Qing Jiang et al. VACCINE
- Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease
- (2009) Amanda C. Cohn et al. CLINICAL INFECTIOUS DISEASES
- Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis
- (2009) Ellen Murphy et al. JOURNAL OF INFECTIOUS DISEASES
- Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis
- (2009) Johan Holst et al. VACCINE
- Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis
- (2009) Susanne Jacobsson et al. VACCINE
- Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease
- (2009) Carl E. Frasch et al. VACCINE
- Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide
- (2009) Lisa K. McNeil et al. VACCINE
- Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086
- (2008) Alessandro Mascioni et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started